Ribociclib is the only CDK4/6 inhibitor with a significant first-line OS benefit (63.9 vs 51.4 months, HR 0.76), while palbociclib, the class founder, never converted its PFS lead into a statistically significant OS gain.
The CDK4/6 inhibitor class defines first-line HR+/HER2- metastatic treatment: palbociclib (Ibrance, Pfizer, 2015), ribociclib (Kisqali, Novartis, 2017) and abemaciclib (Verzenio, Eli Lilly, 2017) are all added to an aromatase inhibitor or fulvestrant. On progression-free survival the three are broadly comparable, but the overall-survival record has separated them. Ribociclib demonstrated a significant OS benefit in MONALEESA-2 (median 63.9 vs 51.4 months, HR 0.76; PMID 35263519) and again in MONALEESA-3 and the premenopausal MONALEESA-7 (PMIDs 31826360, 31166679). Abemaciclib showed an OS signal with fulvestrant in MONARCH-2 (PMID 31563959). Palbociclib's OS analyses (PALOMA-3, PMID 30345905) did not reach statistical significance, a differentiation payers and guidelines increasingly weigh.
The commercial contest has shifted to what happens after CDK4/6 failure, where biomarkers now segment the market. Elacestrant (Orserdu, Stemline/Menarini, 2023), an oral SERD, won in the ESR1-mutant population (EMERALD PFS HR 0.55; PMID 35584336). Alpelisib (Piqray, Novartis, 2019) serves PIK3CA-mutant disease (SOLAR-1; PMID 31091374), and capivasertib (Truqap, AstraZeneca, 2023) serves the broader AKT-pathway-altered group (CAPItello-291; PMID 37256976). Everolimus (Afinitor) plus exemestane (BOLERO-2; PMID 22149876) remains a biomarker-agnostic later-line option. The strategic question is no longer which CDK4/6 inhibitor, but who owns each molecular slice of the second and third line.
Six approved agents define the HR+/HER2- metastatic landscape: three CDK4/6 inhibitors for first line, three biomarker-targeted classes for post-CDK4/6.
| Drug (brand / INN) | Class / mechanism | Company | US approval | Key trial + result | Positioning / line |
|---|---|---|---|---|---|
| Ibrance / palbociclib | CDK4/6 inhibitor (3-wk-on/1-wk-off) | Pfizer | 2015 (first-in-class) | PALOMA-2/-3: PFS gain added to endocrine therapy; OS improvement not statistically significant (PMID 30345905) | 1L or 2L + AI or fulvestrant |
| Kisqali / ribociclib | CDK4/6 inhibitor | Novartis | 2017 | MONALEESA-2: median OS 63.9 vs 51.4 mo, HR 0.76 (PMID 35263519); OS also in MONALEESA-3/-7 | 1L standard; only CDK4/6i with consistent OS |
| Verzenio / abemaciclib | CDK4/6 inhibitor (continuous dosing) | Eli Lilly | 2017 | MONARCH-2: OS benefit + fulvestrant (PMID 31563959); MONARCH-3 final OS (PMID 38729566) | 1L/2L; monotherapy option; adjuvant |
| Orserdu / elacestrant | Oral selective ER degrader (SERD) | Stemline / Menarini | 2023 | EMERALD: PFS HR 0.55 in ESR1-mut, HR 0.70 overall (PMID 35584336) | 2L+ ESR1-mutant after CDK4/6 |
| Piqray / alpelisib | PI3Kalpha inhibitor | Novartis | 2019 | SOLAR-1: PFS 11.0 vs 5.7 mo in PIK3CA-mut, HR 0.65 (PMID 31091374) | 2L PIK3CA-mutant + fulvestrant |
| Truqap / capivasertib | AKT inhibitor | AstraZeneca | 2023 | CAPItello-291: PFS 7.3 vs 3.1 mo AKT-altered, HR 0.50 (PMID 37256976) | Post-AI (+/- CDK4/6), AKT-pathway-altered + fulvestrant |
Sources: FDA Drugs@FDA (Ibrance NDA207103/212436; Kisqali NDA209092; Verzenio NDA208716; Orserdu NDA217639; Piqray NDA212526; Truqap NDA218197). Trial evidence: MONALEESA-2 OS (PMID 35263519), MONALEESA-3 OS (PMID 31826360), MONALEESA-7 OS (PMID 31166679), PALOMA-3 OS (PMID 30345905), MONARCH-3 final OS (PMID 38729566), MONARCH-2 OS (PMID 31563959), EMERALD (PMID 35584336), SOLAR-1 (PMID 31091374), CAPItello-291 (PMID 37256976), BOLERO-2 (PMID 22149876). All PMIDs verified live via PubMed.
What this brief answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- • Head-to-head OS positioning: ribociclib's consistent OS wins (MONALEESA-2/-3/-7) vs palbociclib's non-significant OS • Dosing and tolerability differentiators (continuous abemaciclib vs 3-weeks-on ribociclib/palbociclib)
Delivers
- • ESR1 (elacestrant), PIK3CA (alpelisib), AKT-pathway (capivasertib) segmentation • Overlap and sequencing logic across the three targeted classes
Delivers
- • Palbociclib IRA Medicare negotiation, price effective 2027 • Differentiation levers that defend premium pricing post-negotiation
Custom brief delivered in 72 hours.
Commission This BriefWhat's inside
- Why palbociclib, ribociclib and abemaciclib are not interchangeable despite near-identical first-line PFS gains
- How ESR1, PIK3CA and AKT-pathway biomarkers now split the post-CDK4/6 line among three distinct targeted classes
- Full profiles of Ibrance, Kisqali and Verzenio against elacestrant, alpelisib and capivasertib, spanning 2015 to 2023 approvals
- Dosing and mechanism detail across all six agents, from 3-week-on CDK4/6 schedules to continuous dosing and oral SERD therapy
- Why ribociclib's 63.9 vs 51.4-month OS result in MONALEESA-2 (HR 0.76) sets it apart from palbociclib's non-significant PALOMA-3 OS data
- How MONALEESA-3 and MONALEESA-7 confirm ribociclib's OS pattern while abemaciclib's MONARCH-2 signal remains narrower
- How payers are covering elacestrant for ESR1-mutant, alpelisib for PIK3CA-mutant and capivasertib for AKT-altered disease after CDK4/6 progression
- Why EMERALD's 47.8% ESR1-mutation enrollment rate matters for how narrowly elacestrant's HR 0.55 PFS benefit is targeted
- Why palbociclib's Medicare IRA price negotiation, effective 2027, is the first exclusivity threat to hit the CDK4/6 class
- What differentiation levers, OS data, dosing schedule, each CDK4/6 inhibitor can use to defend premium pricing post-negotiation
- Why the strategic question has moved from which CDK4/6 inhibitor to who owns each biomarker slice in second and third line
- How everolimus plus exemestane from BOLERO-2 still functions as the biomarker-agnostic fallback across ESR1, PIK3CA and AKT segments
Included with every brief
How AXLRx builds this brief
Prepared by MoatRx analysts.
Every AXLRx brief is built from primary regulatory sources (FDA, ClinicalTrials.gov), peer-reviewed literature, and live payer policy documentation — not secondary summaries. No secondary summaries, market research reports, or unverified estimates are used. Findings are independently verified before inclusion.
US Breast Cancer HR+/HER2- Competitive Intelligence sources: FDA Drugs@FDA (approvals and labels), primary trial publications, ClinicalTrials.gov, and live payer/HTA policy documentation.
- Ribociclib first-line OS 63.9 vs 51.4 months, HR 0.76, MONALEESA-2 (PubMed PMID 35263519)
- Elacestrant PFS HR 0.55 in ESR1-mutant, HR 0.70 overall; ESR1 mutation in 47.8% of enrolled, EMERALD (PMID 35584336)
- Capivasertib PFS 7.3 vs 3.1 mo in AKT-pathway-altered (HR 0.50); 7.2 vs 3.6 mo overall (HR 0.60), CAPItello-291 (PMID 37256976)
- Alpelisib PFS 11.0 vs 5.7 mo in PIK3CA-mutant, HR 0.65, SOLAR-1 (PMID 31091374)
- US approvals and sponsors confirmed via FDA Drugs@FDA application records
Frequently asked questions
Commission this brief
AXLRx delivers US Breast Cancer HR+/HER2- competitive intelligence built for pharma and biotech commercial, access, and medical affairs teams. Custom brief in 72 hours.
Use the intake form to specify your indication, geography, and commercial question.
AXLRx analyst confirms scope, comparators, and delivery format.
Research-verified brief in 72 hours with optional analyst readout.